GLAXOSMITHKLINE PLC's ticker is GSK and the CUSIP is 37733W105. A total of 817 filers reported holding GLAXOSMITHKLINE PLC in Q3 2020. The put-call ratio across all filers is 0.91 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $33,000 | +22.2% | 765 | +23.4% | 0.00% | +50.0% |
| Q1 2022 | $27,000 | +17.4% | 620 | +19.2% | 0.00% | 0.0% |
| Q4 2021 | $23,000 | +15.0% | 520 | 0.0% | 0.00% | 0.0% |
| Q3 2021 | $20,000 | -61.5% | 520 | -60.3% | 0.00% | -60.0% |
| Q2 2021 | $52,000 | -43.5% | 1,311 | -49.2% | 0.01% | -50.0% |
| Q1 2021 | $92,000 | -4.2% | 2,583 | -0.8% | 0.01% | -16.7% |
| Q4 2020 | $96,000 | -93.9% | 2,603 | -93.7% | 0.01% | -94.6% |
| Q3 2020 | $1,565,000 | -24.3% | 41,586 | -17.9% | 0.22% | -26.0% |
| Q2 2020 | $2,067,000 | +5.1% | 50,672 | -2.3% | 0.30% | -12.8% |
| Q1 2020 | $1,966,000 | -11.5% | 51,887 | +9.7% | 0.34% | +8.5% |
| Q4 2019 | $2,222,000 | +2.4% | 47,285 | -7.0% | 0.32% | +1.9% |
| Q3 2019 | $2,170,000 | +10.1% | 50,851 | +3.3% | 0.31% | +7.6% |
| Q2 2019 | $1,971,000 | +0.4% | 49,250 | +4.8% | 0.29% | -8.8% |
| Q1 2019 | $1,963,000 | +79.9% | 46,973 | +64.5% | 0.32% | -60.3% |
| Q4 2018 | $1,091,000 | – | 28,551 | – | 0.80% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Healthcare Value Capital, LLC | 100,000 | $3,680,000 | 12.40% |
| Black Creek Investment Management Inc. | 7,443,061 | $273,905,000 | 8.54% |
| KAHN BROTHERS GROUP INC | 1,281,924 | $47,174,803,000 | 8.23% |
| Camber Capital Management LP | 3,500,000 | $128,800,000 | 4.52% |
| Eversept Partners, LP | 946,581 | $35,196,522 | 4.13% |
| EQUITY INVESTMENT CORP | 2,321,164 | $85,419,000 | 3.98% |
| Galibier Capital Management Ltd. | 575,741 | $21,187,000 | 3.66% |
| Keystone Financial Planning, Inc. | 217,399 | $8,000,000 | 3.32% |
| CLIFFORD CAPITAL PARTNERS LLC | 217,817 | $8,016,000 | 3.14% |
| CLARK ESTATES INC/NY | 485,000 | $17,848,000 | 2.52% |